Semax Dosage Guide: Intranasal BDNF Peptide, Half-Life & Cognitive Research Protocol
Semax dosage guide covering intranasal administration, BDNF upregulation research, 0.1% vs 1% concentration comparison, half-life, and cognitive research protocols.
TL;DR — Semax at a Glance
- Semax is a synthetic heptapeptide (MEHFPGP) derived from ACTH(4–10), studied for cognitive enhancement, BDNF upregulation, and neuroprotection
- Standard intranasal research dose: 200–600 mcg/day, typically 1–3 drops of 0.1% solution per nostril
- 0.1% solution delivers ~50 mcg per drop; 1% solution delivers ~500 mcg per drop
- Half-life is extremely short (~2–4 min IV) but intranasal delivery significantly extends CNS exposure via olfactory transport
- Most cognitive research protocols run 14–28 days, often with cycling periods
- Use the reconstitution calculator for custom Semax concentrations →
Disclaimer: Semax is not FDA-approved for human use. This article is for educational and research purposes only — not medical advice.
Semax is a heptapeptide analog of ACTH(4–10) — the sequence Met-Glu-His-Phe-Pro-Gly-Pro — developed in Russia in the 1980s by the Institute of Molecular Genetics in Moscow. It has been approved in Russia and Ukraine for clinical use in stroke, TBI, and cognitive decline, giving it a more developed clinical literature than most research peptides. In the Western research community, it remains an investigational compound used for BDNF modulation, cognitive performance, and neuroprotective research.
Semax Mechanism of Action
Semax operates through several overlapping mechanisms that distinguish it from simpler stimulants or nootropics.
BDNF and NGF Upregulation
The most well-characterized mechanism is Semax's ability to rapidly and potently upregulate Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) expression in the hippocampus and prefrontal cortex. Published rodent research has demonstrated BDNF increases of 2- to 4-fold within hours of administration. BDNF is a key mediator of long-term potentiation (LTP) — the cellular process underlying memory consolidation and synaptic plasticity. Sustained elevation of BDNF is associated with neurogenesis, improved working memory, and faster learning acquisition in animal models.
NGF upregulation plays a distinct but complementary role, particularly in cholinergic neuron maintenance. The basal forebrain cholinergic system is central to attention, learning, and memory. NGF deficiency in these neurons correlates with cognitive decline in Alzheimer's models, and Semax's NGF-upregulating effect has positioned it as a research tool in this area.
Melanocortin Receptor Modulation
Semax is derived from the melanocortin ACTH peptide, and its core sequence retains affinity for melanocortin receptors (MCR), particularly MC4R and MC5R. Melanocortin signaling in the CNS influences dopamine release, motivation, attention, and executive function. This receptor interaction is believed to contribute to the rapid subjective cognitive effects reported in research contexts and may explain the attention-enhancing properties studied in ADHD-related animal models.
Serotonin and Dopamine System Interaction
Semax also modulates serotonergic and dopaminergic tone in ways that are not fully characterized but are supported by neurochemical studies in rodents. Dopamine release in the striatum and prefrontal cortex is transiently elevated following Semax administration, and serotonin turnover in limbic regions is also affected. These neurotransmitter effects may contribute to the anxiolytic and mood-stabilizing properties observed in some research settings.
Semax Dosing Protocols
Standard Cognitive Enhancement Protocol
| Concentration | Drops per Session | Dose per Session | Daily Sessions | Total Daily Dose |
|---|---|---|---|---|
| 0.1% (100 mcg/mL) | 3 drops/nostril | ~150 mcg | 1–2x | 150–300 mcg |
| 0.1% (100 mcg/mL) | 6 drops/nostril | ~300 mcg | 1x | 300 mcg |
| 1% (1000 mcg/mL) | 1 drop/nostril | ~100 mcg | 2–3x | 200–300 mcg |
The most commonly referenced cognitive research dose is 300–600 mcg/day using the 0.1% solution, administered in the morning. Some protocols split doses into morning and early afternoon to extend coverage, though the limited plasma half-life data makes timing optimization difficult without direct CNS PK studies.
Neuroprotective / Acute Protocol
Research examining neuroprotection in ischemia models and TBI contexts uses higher doses, often in the 500–1000 mcg range, delivered acutely. The 1% concentration is standard for these applications due to its higher per-drop delivery. Russian clinical trials for acute ischemic stroke have used doses equivalent to 600–3000 mcg delivered over short intervention windows.
Cycle Duration
Most preclinical cognitive enhancement protocols run 14–28 days followed by an equal or longer off period. The rationale for cycling is the potential for receptor desensitization and the established pattern of diminishing returns observed with continuous melanocortin receptor stimulation. A 4 weeks on / 2 weeks off pattern is commonly referenced in the research literature, though optimal cycling has not been formally studied in controlled trials.
Intranasal Delivery: Pharmacokinetics and Technique
The intranasal route is the primary delivery pathway for Semax in both clinical and research settings. This is not arbitrary — it directly impacts bioavailability and CNS exposure.
Olfactory Transport Pathway
When Semax solution contacts the olfactory epithelium in the upper nasal cavity, peptide molecules are taken up by olfactory receptor neurons. These neurons project directly to the olfactory bulb, which sits adjacent to limbic structures including the hippocampus. This direct olfactory-to-CNS transport pathway allows peptides to reach the brain without crossing the blood-brain barrier through systemic circulation, achieving CNS concentrations disproportionately higher than peripheral plasma levels would predict.
This explains the apparent paradox of Semax's extremely short plasma half-life (2–4 minutes in IV rodent studies) but measurable CNS effects lasting 4–8 hours following intranasal administration. The olfactory transport depot effectively extends CNS exposure.
Administration Technique
Proper intranasal technique maximizes delivery to the olfactory epithelium rather than the lower nasal passage (where it is simply swallowed):
- Clear the nasal passage gently before administration
- Tilt the head slightly forward (not back — this routes drops to the throat rather than the olfactory area)
- Insert the dropper or spray nozzle just inside the nostril, angled toward the nasal septum
- Administer drops and sniff gently to distribute the solution upward
- Alternate nostrils to prevent mucosal irritation from repeated same-site application
Solution pH matters. Semax solutions that are slightly acidic (pH 4–5) have shown better olfactory epithelium penetration in animal models than neutral or basic preparations. Many commercial Russian Semax preparations are formulated with this in mind.
Semax and BDNF: Research Evidence
The BDNF-upregulating effect of Semax has been replicated across multiple independent research groups and represents the most consistent mechanism in the literature.
A landmark study by Dolotov et al. (2006) demonstrated that a single intranasal administration of Semax in rats produced a 2.6-fold increase in BDNF mRNA expression in the hippocampus within 1 hour, sustained for at least 24 hours. This time course differs from direct BDNF administration (which shows faster onset but shorter duration) and suggests Semax may act as a BDNF transcription promoter rather than a direct BDNF substitute.
Subsequent work showed that repeated Semax administration produced cumulative BDNF elevation — meaning levels were higher after 7 days of dosing than after a single dose, suggesting a loading effect. This has important implications for protocol design: the full cognitive effect of a Semax protocol may not be apparent until the second or third week of consistent administration.
BDNF's role in hippocampal neurogenesis also connects Semax research to anxiety and depression models. Higher hippocampal BDNF is associated with reduced anxiety-like behavior in multiple rodent paradigms, and the anxiolytic properties sometimes observed with Semax in clinical reports may be partially explained by this downstream effect.
Semax vs Selank: Comparison
Semax and Selank are both Russian-developed intranasal peptides with overlapping research contexts but distinct primary mechanisms.
| Feature | Semax | Selank |
|---|---|---|
| Primary mechanism | BDNF/NGF upregulation, MCR modulation | Anxiolytic, enkephalin modulation |
| Primary research application | Cognitive enhancement, neuroprotection | Anxiety, stress, mild cognitive support |
| Standard dose (0.1% solution) | 3–6 drops/session | 3 drops/session |
| Onset profile | Stimulatory, relatively activating | Calming, anxiolytic |
| Cycle approach | 14–28 days on / equal off | Flexible, often used acutely |
Researchers interested in both cognitive enhancement and anxiolytic effects sometimes combine both peptides, though this has not been formally studied in controlled settings. The nootropics database has expanded profiles for both compounds.
Storage and Reconstitution Notes
Semax is supplied as either a lyophilized powder or a pre-made solution (common from Russian manufacturers). For powder forms, reconstitution in sterile or bacteriostatic saline is standard. The target concentration determines the final volume.
Use the reconstitution calculator for precise dilution math →
Reconstituted Semax solution should be stored at 2–8°C and protected from light. Stability data for reconstituted solutions suggests a 2–4 week usable window under refrigeration with BAC water. Lyophilized powder is stable at -20°C for 12+ months. Do not freeze reconstituted solutions as peptide aggregation may occur.
Frequently Asked Questions
Q: How many drops of Semax 0.1% per day is standard? A: Most cognitive research protocols use 3–6 drops per nostril (or 6–12 drops total) of 0.1% Semax once daily, delivering approximately 300–600 mcg. Some researchers split this into morning and midday sessions. The 0.1% concentration delivers approximately 50 mcg per drop based on a standard nasal drop volume of 50 µL.
Q: Does Semax cause tolerance? A: Animal model data suggests that continuous Semax administration can produce melanocortin receptor downregulation over extended periods, supporting the cycling approach used in most protocols. The BDNF upregulation effect appears more durable, but the subjective activating effects associated with MCR stimulation are more likely to diminish with continuous daily use.
Q: Can Semax and Selank be used together? A: These peptides are frequently referenced together in research contexts due to their complementary mechanisms — Semax for cognitive activation and neuroprotection, Selank for anxiolytic stabilization. They are administered separately (in different nostrils or at different times) rather than mixed. Combined protocols have not been formally studied but are widely discussed in the research literature.
Tools for your research:
→ Open the Reconstitution Calculator
Research Disclaimer: Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are for research purposes only. Consult a qualified healthcare provider before use.
Written by the Peptide Performance Calculator Research Team
Our team compiles research guides based on published literature for educational purposes. All content is for research use only — not medical advice. Read our disclaimer.
Frequently Asked Questions
What is a typical Semax research dose?
Research protocols typically use 200–600 mcg per day intranasally. The most common dose is 300 mcg/day split across both nostrils. The 0.1% concentration delivers approximately 50 mcg per drop.
How does intranasal Semax reach the brain?
Intranasal delivery leverages the olfactory epithelium pathway, allowing peptides to bypass the blood-brain barrier and reach the CNS more directly than intravenous or subcutaneous routes.
What is the half-life of Semax?
Semax has an estimated plasma half-life of approximately 2–4 minutes following intravenous administration in animal models. Intranasal delivery appears to extend CNS exposure substantially due to direct olfactory transport, but precise intranasal pharmacokinetics remain under investigation.
What is the difference between Semax 0.1% and 1%?
Semax 0.1% delivers approximately 50 mcg per drop and is used for daily cognitive research protocols. Semax 1% delivers approximately 500 mcg per drop and is more commonly used in acute neuroprotective or stroke-related research contexts.
New compound guides and calculator updates — no spam, unsubscribe any time.
Free Peptide Calculators
7 free calculators covering reconstitution, dosage, syringe units, half-life, injection volume, stack planning, and cycle duration — no account needed.